- Conditions
- Thyroid Eye Disease
- Interventions
- VRDN-003, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 50
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Thyroid-associated Ophthalmopathy
- Interventions
- Rituximab, Saline, Methylprednisolone
- Drug
- Lead sponsor
- Rebecca Bahn
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Graves' Disease
- Interventions
- Radiotherapy, Sham treatment
- Radiation
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 30 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 1998
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Interventions
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Device
- Lead sponsor
- THYROSCOPE INC.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Thyroid Eye Disease
- Interventions
- Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
- Interventions
- TEPEZZA, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Graves' Ophthalmopathy (GO)
- Interventions
- RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
- Drug · Other
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
- Conditions
- Thyroid Eye Disease
- Interventions
- VRDN-003, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 37
- States / cities
- Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Interventions
- Prostaglandin Analog, Timolol
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Thyroid Eye Disease
- Interventions
- Kamuvudine-9
- Drug
- Lead sponsor
- Peter Timoney
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Thyroid Eye Disease
- Interventions
- Satralizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- San Diego, California • Danbury, Connecticut • Chicago, Illinois + 3 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Thyroid Eye Disease
- Interventions
- SENSIMED Triggerfish
- Device
- Lead sponsor
- Sensimed AG
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Thyroid Eye Disease
- Interventions
- AMG 732, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more
- Conditions
- Thyroid Eye Disease
- Interventions
- TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG
- Drug · Other
- Lead sponsor
- Tourmaline Bio, Inc., a Novartis Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Pasadena, California • Sacramento, California + 12 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Newport Beach, California • Palo Alto, California + 13 more
- Conditions
- Thyroid Eye Disease, TED, Graves Orbitopathy
- Interventions
- linsitinib, Placebo
- Drug
- Lead sponsor
- Sling Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Thyroid Eye Disease (TED)
- Interventions
- VRDN-003, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
- Conditions
- Bioavailability, Bioequivalence
- Interventions
- TEPEZZA, EDP
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more